Anvisa bans medicines after suspicion of quality and insect

The second is an anesthetic from Hypofarma. In batch 25010360, valid until January 2027, the presence of an unidentified insect inside a bottle was reported, which led to the immediate ban.

The closures are precautionary and temporary. According to Anvisa, the objective is to protect the population while additional tests and analyzes are carried out. Until the investigations are completed, the products must not be sold or used.

Professionals and patients were advised to collaborate. Suspected cases can be reported through Anvisa’s service channels or to local Health Surveillance.

Other side

In a note to Facto News, Hypofarma denies the presence of insects in the medicine. The company states that it carried out detailed technical analyzes and “it was found that there was no presence of any insect in the ampoule. The appropriate responses were officially forwarded to the regulatory body (Anvisa), as soon as we became aware”, says the company in a note.

Additionally, the client who had made the initial complaint recanted what had happened. Hypofarma reiterates its ongoing commitment to the highest quality and safety standards in all its products, always valuing transparency in its relationships with regulatory authorities, partners and consumers. Hypofarma, in note